[go: up one dir, main page]

NO974685L - Acetamidderivater, fremgangsmåte for fremstilling av disse, og farmasöytisk preparat inneholdende disse - Google Patents

Acetamidderivater, fremgangsmåte for fremstilling av disse, og farmasöytisk preparat inneholdende disse

Info

Publication number
NO974685L
NO974685L NO974685A NO974685A NO974685L NO 974685 L NO974685 L NO 974685L NO 974685 A NO974685 A NO 974685A NO 974685 A NO974685 A NO 974685A NO 974685 L NO974685 L NO 974685L
Authority
NO
Norway
Prior art keywords
processes
preparation
pharmaceutical compositions
compositions containing
acetamide derivatives
Prior art date
Application number
NO974685A
Other languages
English (en)
Other versions
NO310619B1 (no
NO974685D0 (no
Inventor
Teruya Murata
Katsuhiko Hino
Makato Oka
Mari Itoh
Kiyoshi Furukawa
Original Assignee
Dainippon Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Pharmaceutical Co filed Critical Dainippon Pharmaceutical Co
Publication of NO974685D0 publication Critical patent/NO974685D0/no
Publication of NO974685L publication Critical patent/NO974685L/no
Publication of NO310619B1 publication Critical patent/NO310619B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
NO19974685A 1995-04-13 1997-10-10 Acetamidderivater og farmasöytisk preparat inneholdende disse NO310619B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP11393795 1995-04-13
PCT/JP1996/000977 WO1996032383A1 (en) 1995-04-13 1996-04-10 Acetamide derivatives, process for producing the same, and medicinal composition containing the same

Publications (3)

Publication Number Publication Date
NO974685D0 NO974685D0 (no) 1997-10-10
NO974685L true NO974685L (no) 1997-12-12
NO310619B1 NO310619B1 (no) 2001-07-30

Family

ID=14624947

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19974685A NO310619B1 (no) 1995-04-13 1997-10-10 Acetamidderivater og farmasöytisk preparat inneholdende disse

Country Status (25)

Country Link
US (1) US5972946A (no)
EP (1) EP0826673B1 (no)
KR (1) KR100433589B1 (no)
CN (1) CN1094929C (no)
AR (1) AR002289A1 (no)
AT (1) ATE228113T1 (no)
AU (1) AU694647B2 (no)
BR (1) BR9604894A (no)
CA (1) CA2218033A1 (no)
CZ (1) CZ289093B6 (no)
DE (1) DE69624916T2 (no)
DK (1) DK0826673T3 (no)
ES (1) ES2187644T3 (no)
HU (1) HUP9801688A3 (no)
IL (1) IL117659A (no)
NO (1) NO310619B1 (no)
NZ (1) NZ304982A (no)
PL (1) PL322819A1 (no)
PT (1) PT826673E (no)
RO (1) RO117532B1 (no)
RU (1) RU2160256C2 (no)
SK (1) SK281840B6 (no)
TW (1) TW450963B (no)
WO (1) WO1996032383A1 (no)
ZA (1) ZA962438B (no)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ292269A (en) * 1994-09-09 1998-09-24 Nippon Shinyaku Co Ltd Heterocyclic amine derivatives and medicaments therefrom
KR100562808B1 (ko) 1997-08-04 2006-03-21 다이쇼 세이야꾸 가부시끼가이샤 아릴옥시아닐린 유도체
WO1999026614A1 (en) 1997-11-21 1999-06-03 Euro-Celtique S.A. Substituted 2-aminoacetamides and the use thereof
ZA9810490B (en) 1997-12-03 1999-05-20 Dainippon Pharmaceutical Co 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor
FR2778564B1 (fr) * 1998-05-13 2001-07-13 Sanofi Sa Utilisation de composes reduisant l'apoptose
WO1999058117A1 (fr) * 1998-05-13 1999-11-18 Sanofi-Synthelabo Utilisation de composes reduisant l'apoptose
JP2002241369A (ja) * 1998-05-18 2002-08-28 Dainippon Pharmaceut Co Ltd ４−ピリミジニルアミノアセトアミド誘導体及びそれを含有する医薬組成物
DE19853278A1 (de) 1998-11-19 2000-05-25 Aventis Pharma Gmbh Substituierte 4-Amino-2-aryl-cyclopenta[d]pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
WO2000037085A1 (en) 1998-12-18 2000-06-29 Scios Inc. Treatment of diseases involving cyst formation
DE69932449T2 (de) 1998-12-18 2007-03-15 Scios Inc., Fremont Agonisten und antagonisten von benzodiazepinrezeptoren des peripheren typs
EP1607744A3 (en) * 1998-12-18 2009-09-30 Scios Inc. Treatment of diseases involving cyst formation with combinations comprising a PTBR agonist
CA2357781A1 (en) 1999-01-22 2000-07-27 Elan Pharmaceuticals, Inc. Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4
EP1147091A2 (en) 1999-01-22 2001-10-24 Elan Pharmaceuticals, Inc. Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4
PL350050A1 (en) 1999-01-22 2002-10-21 Elan Pharm Inc Acyl derivatives which treat vla-4 related disorders
US6436904B1 (en) * 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
DE19904710A1 (de) 1999-02-05 2000-08-10 Aventis Pharma Gmbh Substituierte 4-Amino-2-aryl-tetrahydrochinazoline, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
AU3246600A (en) 1999-03-01 2000-09-21 Elan Pharmaceuticals, Inc. Alpha-aminoacetic acid derivatives useful as alpha 4 beta 7 receptor antagonists
US7037916B2 (en) 1999-07-15 2006-05-02 Pharmacopeia Drug Discovery, Inc. Pyrimidine derivatives as IL-8 receptor antagonists
NZ518702A (en) 1999-11-17 2004-04-30 Dainippon Pharmaceutical Co [5-chloro-6-phenyl-2-(4-trifluoromethylphenyl)-4-pyrimidinylamino]acetamide derivatives, process for producing the same, medicinal compositions containing the same and intermediate of these compounds
US20020072521A1 (en) * 2000-03-16 2002-06-13 Taeyoung Yoon 5-substituted arylpyrimidines
EP1301490A2 (en) 2000-07-18 2003-04-16 Neurogen Corporation 5-substituted 2-aryl-4-pyrimidinones
ES2242771T5 (es) * 2000-09-15 2011-10-14 Vertex Pharmaceuticals Incorporated Compuestos de pirazol útiles como inhibidores de proteína quinasas.
EP1698627A1 (en) * 2000-09-15 2006-09-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
ZA200301703B (en) * 2000-09-15 2004-03-02 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors.
RU2340611C2 (ru) * 2000-09-15 2008-12-10 Вертекс Фармасьютикалз Инкорпорейтед Производные пиразола, используемые в качестве ингибиторов протеинкиназы
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
CN102250071A (zh) * 2000-12-21 2011-11-23 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的吡唑化合物
WO2003049739A1 (en) * 2001-12-07 2003-06-19 Vertex Pharmaceuticals, Inc. Pyrimidine-based compounds useful as gsk-3 inhibitors
CA2475633C (en) * 2002-02-06 2013-04-02 Vertex Pharmaceuticals Incorporated Heteroaryl compounds useful as inhibitors of gsk-3
WO2003072107A1 (en) * 2002-02-22 2003-09-04 Pharmacia & Upjohn Company Substituted pyrimidinones and pyrimidinthiones
AU2003218215A1 (en) * 2002-03-15 2003-09-29 Vertex Pharmaceuticals, Inc. Azolylaminoazines as inhibitors of protein kinases
TWI281470B (en) * 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
TW200307671A (en) * 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
AU2003257078B2 (en) 2002-08-02 2010-04-01 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of GSK-3
PL377474A1 (pl) * 2002-12-13 2006-02-06 F. Hoffmann-La Roche Ag Pochodne 3H-chinazolin-4-onu
ES2295816T3 (es) 2003-01-14 2008-04-16 Arena Pharmaceuticals, Inc. Derivados arilo y heteroarilo 1,2,3-trisustituidos como moduladores del metabolismo, y profilaxis y tratamiento de transtornos relacionados con los mismos, tales como la diabetes y la hiperglucemia.
WO2004072029A2 (en) * 2003-02-06 2004-08-26 Vertex Pharmaceuticals Incorporated Pyrazolopyridazines useful as inhibitors of protein kinases
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
JP4808156B2 (ja) * 2003-08-05 2011-11-02 バーテックス ファーマシューティカルズ インコーポレイテッド 電位依存型イオンチャネルの阻害剤としての縮合ピリミジン化合物
US7378409B2 (en) * 2003-08-21 2008-05-27 Bristol-Myers Squibb Company Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
AU2004297235A1 (en) * 2003-12-04 2005-06-23 Vertex Pharmaceuticals Incorporated Quinoxalines useful as inhibitors of protein kinases
KR20060129023A (ko) * 2004-02-23 2006-12-14 다이닛본 스미토모 세이야꾸 가부시끼가이샤 신규한 헤테로환 화합물
GT200600005A (es) * 2005-01-12 2006-08-16 Un derivado de 2-(aminocarbonilo ciclico)-indolina y una composicion farmaceutica que lo contiene
US7737151B2 (en) * 2005-08-18 2010-06-15 Vertex Pharmaceuticals Incorporated Pyrazine kinase inhibitors
KR20080059268A (ko) 2005-09-29 2008-06-26 엘란 파마슈티칼스, 인크. Ｖｌａ-4에 의해 매개되는 백혈구 부착을 억제하는피리미디닐 아미드 화합물
ATE502031T1 (de) 2005-09-29 2011-04-15 Elan Pharm Inc Carbamatverbindungen, die die durch vla-4 vermittelte leukozytenadhäsion inhibieren
AR056763A1 (es) * 2005-11-03 2007-10-24 Vertex Pharma Aminopirimidinas sustituidas con tiazol o pirazol,utiles como agentes anticancer y composiciones farmaceuticas que las contienen.
WO2007054453A2 (en) * 2005-11-11 2007-05-18 F. Hoffmann-La Roche Ag Carbocyclic fused cyclic amines as inhibitors of the coagulation factor xa
TWI389904B (zh) 2006-02-27 2013-03-21 Elan Pharm Inc 抑制由ｖｌａ-４所調節的白血球黏附之嘧啶磺醯胺化合物
RU2451673C2 (ru) * 2006-03-29 2012-05-27 Ф. Хоффманн-Ля Рош Аг ПРОИЗВОДНЫЕ ПИРИДИНА И ПИРИМИДИНА В КАЧЕСТВЕ АНТАГОНИСТОВ mGluR2
WO2008057940A1 (en) * 2006-11-02 2008-05-15 Vertex Pharmaceuticals Incorporated Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases
CA2673353A1 (en) * 2006-12-19 2008-06-26 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
EP1941879A1 (en) * 2007-01-05 2008-07-09 PAION Deutschland GmbH Neuroprotective agent for the treatment of neuronal damage
EP2134707B1 (en) * 2007-03-09 2013-09-11 Vertex Pharmaceuticals, Inc. Aminopyrimidines useful as inhibitors of protein kinases
JP2010520887A (ja) 2007-03-09 2010-06-17 バーテックス ファーマシューティカルズ インコーポレイテッド 蛋白キナーゼの阻害剤として有用なアミノピリジン
JP5393489B2 (ja) * 2007-03-09 2014-01-22 バーテックス ファーマシューティカルズ インコーポレイテッド 蛋白キナーゼの阻害剤として有用なアミノピリミジン
WO2008116139A2 (en) 2007-03-22 2008-09-25 Vertex Pharmaceuticals Incorporated N-heterocyclic compounds useful as inhibitors of janus kinases
MX2009011059A (es) 2007-04-13 2009-11-26 Vertex Pharma Aminopirimidinas utiles como inhibidores de cinasas.
EP2155730A2 (en) * 2007-05-02 2010-02-24 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
NZ580884A (en) 2007-05-02 2012-02-24 Vertex Pharma Thiazoles and pyrazoles useful as kinase inhibitors
AU2008247594A1 (en) * 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
AU2008257044A1 (en) * 2007-05-24 2008-12-04 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
AR067762A1 (es) * 2007-07-31 2009-10-21 Vertex Pharma Proceso para preparar 5-fluoro-1h-pirazolo (3,4-b) piridin-3-amina y derivados de la misma
ES2676289T3 (es) 2008-06-19 2018-07-18 Takeda Pharmaceutical Company Limited Compuesto heterocíclico y su uso
WO2010027921A1 (en) * 2008-09-03 2010-03-11 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same
WO2010068794A2 (en) 2008-12-10 2010-06-17 The General Hospital Corporation Hif inhibitors and use thereof
EP2424841A1 (en) * 2009-04-27 2012-03-07 Elan Pharmaceuticals Inc. Pyridinone antagonists of alpha-4 integrins
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
JP2013032290A (ja) * 2009-11-20 2013-02-14 Dainippon Sumitomo Pharma Co Ltd 新規縮合ピリミジン誘導体
EP2619198A1 (en) 2010-09-22 2013-07-31 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
JP2013542243A (ja) 2010-11-15 2013-11-21 カトリーケ ウニヴェルシテイト ルーヴェン 新規な抗ウイルス性化合物
PL3242666T3 (pl) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
JP6838744B2 (ja) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩
KR102859841B1 (ko) 2018-06-06 2025-09-12 아레나 파마슈티칼스, 인크. S1p1 수용체와 관련된 병태의 치료 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3631036A (en) * 1969-11-04 1971-12-28 American Home Prod 5-amino-2 6-substituted-7h-pyrrolo(2 3-d) pyrimidines and related compounds
US3631045A (en) * 1969-11-04 1971-12-28 American Home Prod 4 5-diamino-7h-pyrrolo(2 3-d)pyrimidine derivatives
FR2263750A1 (en) * 1974-03-12 1975-10-10 Delalande Sa N-phenyl-N-(2-aryl-6-methyl-pyrimidin-4-yl)amino acid derivs. - useful e.g. as analeptics, hypotensives, analgesics, etc.
FR2525595A1 (fr) * 1982-04-27 1983-10-28 Pharmuka Lab Nouveaux derives d'arene et d'heteroarenecarboxamides et leur utilisation comme medicaments
FR2582514B1 (fr) * 1985-05-30 1988-02-19 Rhone Poulenc Sante Medicaments a base d'amides, nouveaux amides et leur preparation
DK273689A (da) * 1988-06-06 1989-12-07 Sanofi Sa 4-amino-3-carboxyquinoliner og -naphthyridiner, fremgangsmaade til deres fremstilling og anvendelse deraf i laegemidler
JPH07165721A (ja) * 1993-12-15 1995-06-27 Sumitomo Chem Co Ltd 放射性イソキノリンカルボキサミド誘導体

Also Published As

Publication number Publication date
ATE228113T1 (de) 2002-12-15
DE69624916D1 (de) 2003-01-02
HUP9801688A2 (hu) 1999-03-29
EP0826673A1 (en) 1998-03-04
TW450963B (en) 2001-08-21
SK137497A3 (en) 1998-05-06
RU2160256C2 (ru) 2000-12-10
BR9604894A (pt) 1998-07-14
SK281840B6 (sk) 2001-08-06
AU5287496A (en) 1996-10-30
CA2218033A1 (en) 1996-10-17
CZ322397A3 (cs) 1998-02-18
IL117659A (en) 2000-12-06
NO310619B1 (no) 2001-07-30
DE69624916T2 (de) 2003-04-24
WO1996032383A1 (en) 1996-10-17
ES2187644T3 (es) 2003-06-16
CN1186487A (zh) 1998-07-01
EP0826673A4 (en) 1998-09-02
KR100433589B1 (ko) 2004-09-13
KR19980703815A (ko) 1998-12-05
NO974685D0 (no) 1997-10-10
PT826673E (pt) 2003-02-28
AU694647B2 (en) 1998-07-23
US5972946A (en) 1999-10-26
AR002289A1 (es) 1998-03-11
ZA962438B (en) 1996-10-01
CZ289093B6 (cs) 2001-10-17
RO117532B1 (ro) 2002-04-30
NZ304982A (en) 1999-03-29
HUP9801688A3 (en) 2001-11-28
PL322819A1 (en) 1998-02-16
IL117659A0 (en) 1996-07-23
CN1094929C (zh) 2002-11-27
DK0826673T3 (da) 2003-03-24
EP0826673B1 (en) 2002-11-20

Similar Documents

Publication Publication Date Title
NO974685D0 (no) Acetamidderivater, fremgangsmåte for fremstilling av disse, og farmasöytisk preparat inneholdende disse
NO975987D0 (no) 4-Fenylaminotiazol-derivater, fremgangsmåte for fremstilling av disse og farmasöytiske blandinger inneholdende nevnte derivater
NO20001409D0 (no) Karboksamidotiazolderivater, fremgangsmåte for fremstilling derav og farmasøytiske blandinger
DK1156049T3 (da) Substituerede heterocykliske forbindelser, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
NO307707B1 (no) Spiroazabicykliske forbindelser, farmasøytisk preparat inneholdende slike forbindelser og anvendelse derav
NO307827B1 (no) Benzoksazol- og pyridinderivater, anvendelse av dem og farmasøytisk preparat inneholdende dem
NO981817L (no) Indolin-2-on-derivater, fremgangsmÕte for fremstilling av dem og farmas÷ytiske blandinger inneholdende dem
FI953898A7 (fi) Glysiiniamidijohdannaisia, menetelmiä niiden valmistamiseksi ja niitä sisältäviä lääkeaineita
DK0885204T3 (da) Nye arylglycinamidderivater, fremgangsmåde til fremstilling deraf og farmaceutiske præparater indeholdende disse forbindelser
FI952550A7 (fi) Uudet N-pyridyylikarboksamidit ja johdannaiset, menetelmät niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
HUP9602635A3 (en) 4-aciloxy-benzenesulfonamide derivatives, process for their preparation and pharmaceutical compositions containing them
FI943688L (fi) Uudet 11-bentsaldoksiimi-17beta-metoksi-27alfa-metoksi-metyyli-estradieenijohdannaiset, menetelmät niiden valmistamiseksi ja näitä sisältävät lääkeaineet
NO950537D0 (no) Polysubstituerte 3-acylamino-5-fenyl-1,4-benzodiazepin-2-on-derivater, fremgangsmåter for fremstilling derav og farmasöytiske blandinger inneholdende dem
EE03825B1 (et) 2-tsüanoiminoimidasooli derivaadid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
FI941836A7 (fi) 3-deoksioligosakkaridit, menetelmiä niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
NO961000D0 (no) Piperidinderivater, fremgangsmåte for fremstilling derav og medikament og preparat inneholdende slike
HUP9901485A3 (en) Heterocyclylcarboxamide derivatives, pharmaceutical compositions containing the same, process for their preparation and their use
NO955320D0 (no) Substituerte 4-fenyltiazolderivater, fremgangsmåte for fremstilling derav og farmasöytiske blandinger som inneholder dem
DK0735042T3 (da) Maltitolsammensætning og fremgangsmåde til fremstilling deraf
IL117495A0 (en) Beta-alanine derivatives processes for the preparation thereof and pharmaceutical compositions containing the same
NO970136D0 (no) Granulös formulering inneholder mikroorganismer, fremgangsmåte for fremstilling og anvendelse derav
FI972988A0 (fi) Menetelmiä ja farmaseuttisia koostumuksia, joissa käytetään desmetyyliselegiliiniä
FI960316L (fi) Oksatiolaanit, menetelmä niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
DK0806949T3 (da) Ny farmaceutisk komposition, der indeholder trimebutin, og fremgangsmåde til fremstilling deraf
FI944751L (fi) Heteroaryylipiperidiinejä, menetelmä niiden valmistamiseksi ja niitä sisältäviä farmaseuttisia koostumuksia

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN OCTOBER 2003